Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1 Pivotal Phase 3 CYPRESS study enrollment on track to complete by late summer Completed sale o...
How might the sale of the TRELEGY royalty interest affect the company’s valuation multiples (P/E, EV/EBITDA) going forward?
What are the tax implications of the TRELEGY royalty sale on the company's net income?
What is the outlook for the remaining pipeline assets beyond CYPRESS—any upcoming INDs or trials?
26 days ago